Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD trimmed its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 33.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 348,173 shares of the company's stock after selling 178,585 shares during the quarter. Cellebrite DI accounts for about 1.8% of Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD's holdings, making the stock its 20th largest position. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD owned about 0.17% of Cellebrite DI worth $7,664,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. True Wind Capital Management L.P. lifted its stake in shares of Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock valued at $305,358,000 after acquiring an additional 2,130,386 shares during the last quarter. FMR LLC grew its holdings in shares of Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company's stock worth $94,586,000 after acquiring an additional 3,239,307 shares during the period. Pembroke Management LTD boosted its position in shares of Cellebrite DI by 4.4% in the 4th quarter. Pembroke Management LTD now owns 1,992,432 shares of the company's stock worth $43,893,000 after purchasing an additional 84,087 shares in the last quarter. Principal Financial Group Inc. bought a new position in Cellebrite DI during the 3rd quarter valued at approximately $23,402,000. Finally, Two Sigma Advisers LP increased its position in Cellebrite DI by 9.8% during the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock valued at $22,584,000 after buying an additional 120,000 shares in the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.
Cellebrite DI Stock Up 2.7 %
CLBT stock opened at $17.23 on Wednesday. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The company's 50-day simple moving average is $21.67 and its 200-day simple moving average is $19.72. The firm has a market cap of $3.55 billion, a P/E ratio of -12.40, a PEG ratio of 4.27 and a beta of 1.53.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on CLBT. Needham & Company LLC restated a "buy" rating and issued a $28.00 price target on shares of Cellebrite DI in a research note on Monday. Lake Street Capital raised their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $23.43.
View Our Latest Stock Analysis on CLBT
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
